Direct-to-Patient Survey Results Summary
Health Care, Innovation, Supply Chain
During the 2022 GCSG US conference in San Antonio, 65 attendees participated in our Direct-to-Patient (DtP) survey. While 2/3rd’s of the respondents represented pharmaceutical companies / sponsors, there is also a strong mix of input from service providers. Over 50% of participants also had experience with DtP. Though a need for technology improvements was noted, our industry’s adoption of patient centric services like DTP continues to boost the growth of decentralized trials.
Related Education Resources.
All ResourcesEMA Guidance on Trial Mgmt during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
FDA Policy for REMS Reqmts during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
Lessons Learned: Conducting COVID Clinical Trials and Building a Clinical Supplies Team During the Peak of the Pandemic
Topics: Conference, COVID-19
Executive Summary
Members
